Formerly known as Spiden, Liom is pioneering the development of the world’s first non-invasive glucose-monitoring wearable providing accurate glucose measurements. The company has secured $25 million in an ongoing series A funding round to develop and test the device, aiming for a pre-launch in early 2026..

Liom以前被称为Spiden，是世界上第一款无创血糖监测可穿戴设备的先驱，可提供准确的血糖测量。该公司已在正在进行的A系列融资回合中获得2500万美元，用于开发和测试该设备，目标是在2026年初进行预发布。

Founded in 2017 by serial entrepreneur Leo Grünstein, Liom, with offices in Pfäffikon SZ and San Francisco has raised over USD 55m in equity funding to-date and employs a team of >80 FTE. The company has kicked-off a USD 50-70m Series A, of which USD >25m have already been secured. This will allow Liom to develop and test its wrist-worn prototype on 100+ people by end of 2025 and launch a pre-launch sales campaign of its wearable in H1 2026, the world's first non-invasive glucose monitoring device that offers accurate glucose measurements without the need for invasive per-subject calibration using a needle, putting it ahead of established players in the wearable business, such as Apple, Samsung and Google..

Liom由连续创业者Leo Grünstein于2017年成立，在Pfäffikon SZ和旧金山设有办事处，迄今已筹集超过5500万美元的股权资金，并拥有一支超过80名全职员工的团队。该公司启动了5000万至7000万美元的a系列，其中2500万美元以上已经获得担保。这将使Liom能够在2025年底之前在100多人身上开发和测试其腕带原型，并在2026年上半年启动其可穿戴设备的上市前销售活动，这是世界上第一款无创血糖监测设备，可提供准确的血糖测量，而无需使用针头对每个受试者进行有创校准，使其领先于苹果、三星和谷歌等可穿戴业务的老牌玩家。

Multiple internal and external studies conducted throughout 2024 with >60 subjects have demonstrated the device’s capability. In a recent third-party validation study, Liom's proprietary benchtop system and AI algorithms demonstrated a MARD (Mean Absolute Relative Difference) of 14.5% without any per-subject calibration (publication pre-print available here).

在2024年进行的多项内部和外部研究中，有60多名受试者证明了该设备的功能。在最近的第三方验证研究中，Liom专有的台式系统和AI算法显示MARD（平均绝对相对差异）为14.5%，没有任何受试者校准（此处可提供出版物预印）。

MARD is the percentage error to the reference measurement, which in this case is a catheter-derived venous measurement. The light-& AI-only measurements show excellent agreement with reference blood glucose values for a wide range of glucose levels and time series. Using per-subject calibration, the MARD attained was even lower, at 7%..

MARD是参考测量的百分比误差，在这种情况下是导管衍生的静脉测量。对于广泛的葡萄糖水平和时间序列，仅光和AI测量显示与参考血糖值非常吻合。使用每个受试者的校准，获得的MARD甚至更低，为7%。

This performance is comparable to the first generation of needle-based continuous glucose monitoring (CGM) devices, which, after 10 years of optimization, have gradually reached the 10% MARD level. Currently, these devices, predominantly sold by the two medtech giants Abbott and Dexcom, dominate the strongly growing CGM market of USD >10bn that is attempting expansion towards healthy consumers, despite requiring replacement of its needle-based technology every 10–14 days.

这种性能与第一代基于针头的连续血糖监测（CGM）设备相当，经过10年的优化，该设备已逐渐达到10%的MARD水平。目前，这些设备主要由两家医疗科技巨头雅培（Abbott）和德克斯康（Dexcom）销售，在规模超过100亿美元的CGM市场上占据主导地位，该市场正试图向健康消费者扩张，尽管需要每10-14天更换一次针基技术。

Liom sees significant potential for further improvement of its performance in the near term, enabled by its purely light- and AI-driven approach that allows for rapid iteration..

Liom认为其性能在短期内有进一步提高的巨大潜力，这是由其纯粹的轻型和人工智能驱动的方法实现的，该方法允许快速迭代。

Leveraging the company’s proprietary light- and AI-based technology, the device provides additional health metrics, such as heart rate and movement, enabling consumers looking to optimize an active, healthy lifestyle, improve their habits, or mitigate the risk of developing health conditions. Further biomarkers, including macronutrients like lipids and proteins, as well as ketones, hydration, and lactate, will be added to the device, paving the way for even broader applications.(Press release/RAN).

利用该公司专有的基于光线和人工智能的技术，该设备提供了额外的健康指标，如心率和运动，使消费者能够优化积极健康的生活方式，改善习惯，或减轻发展健康状况的风险。进一步的生物标志物，包括脂质和蛋白质等常量营养素，以及酮，水合作用和乳酸，将被添加到该设备中，为更广泛的应用铺平道路。（新闻稿/运行）。